Shionogi joins CMAC as a Tier 1 Partner, advancing pharmaceutical innovation and digital transformation of chemistry manufacturing & controls
As a leading Japanese research-driven pharmaceutical company, Shionogi is globally recognised for its commitment to innovation and to addressing unmet medical needs. Its entry into the CMAC consortium marks a significant milestone, amplifying its research impact, accelerating technology translation, and deepening international collaboration. Shionogi also brings critical insights from the Japanese regulatory environment, further enhancing CMAC’s global perspective.
By joining CMAC’s prestigious network of Tier 1 partners, including AstraZeneca, Chiesi, Lilly, Pfizer, Roche, Sanofi, Takeda, and UCB, Shionogi gains access to advanced research infrastructure, collaborative pre-competitive projects, knowledge-sharing platforms, PhD placements, mentorship programmes, and strategic translation to industry initiatives designed to deliver transformational outcomes.
Shionogi’s membership strengthens CMAC’s global footprint and collective capacity to drive innovation. Their engagement will be instrumental in advancing our translation efforts, including the progression of the CMAC CMC DataFactory™ portfolio and Quality by Digital Design solutions to higher technology readiness levels.
We are excited to grow this partnership and to shape the next chapter together.
“Shionogi is excited to join CMAC to collaborate in the field of advanced CMC technologies. Through this partnership, we aim to bring our CMC capabilities to the next stage, driving greater efficiency and innovation in pharmaceutical development. We look forward to working with CMAC to realise these goals and contribute to the evolution of sustainable and cost-effective manufacturing practices.”
“We are delighted to welcome Shionogi into CMAC’s Tier 1 industry portfolio. As a global leader in pharmaceuticals with a strong track record in innovation, Shionogi brings valuable insights, particularly to accelerate the commercial readiness and high TRL testing of our CMC DataFactory™. Their membership represents a strategic step forward in expanding CMAC’s global reach and accelerating the translation of cutting-edge science into scalable, impactful solutions. Together, we aim to shape the future of pharmaceutical manufacturing through shared vision, advanced CMC capabilities, and an ecosystem built on collaboration and translational excellence.”